SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-005950 to IM Cannabis Corp. (IMCC)

IM Cannabis Corp.
Date: June 12, 2026 · CIK: 0001792030 · Accession: 0000000000-26-005950

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-296637

Date
June 12, 2026
Author
Division of
Form
UPLOAD
Company
IM Cannabis Corp.

Letter

Re: IM Cannabis Corp. Registration Statement on Form F-3 Filed June 9, 2026 File No. 333-296637 Dear Oren Shuster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions.

June 12, 2026

Oren Shuster Chief Executive Officer IM Cannabis Corp. 3606-833 Seymour Street Vancouver, British Columbia V6B 0G4, Canada

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ilana Levin, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                            June 12, 2026

Oren Shuster
Chief Executive Officer
IM Cannabis Corp.
3606-833 Seymour Street
Vancouver, British Columbia
V6B 0G4, Canada

        Re: IM Cannabis Corp.
            Registration Statement on Form F-3
            Filed June 9, 2026
            File No. 333-296637
Dear Oren Shuster:
       This is to advise you that we have not reviewed and will not review your
registration
statement.
       Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Ilana Levin, Esq.
</TEXT>
</DOCUMENT>